Patent Assignment
Reel/Frame 051671/0536
Assignment of Assignor's Interest
Recorded: 2020-01-30
Pages: 17
Assignor
RECRO PHARMA, INC.
Executed: 2019-11-21
Assignee
BAUDAX BIO, INC.
490 LAPP ROAD, MALVERN, PENNSYLVANIA, 19355
Covered Properties
(32)
Reduction of Intravenously Administered Nanoparticulate-Formulation- Induced Adverse Physiological Reactions
Patent:
5,834,025 →
Application:
08/696,754 →
Nanoparticulate Compositions Having Lysozyme as a Surface Stabilizer
Imidazol Derivatives Having Affinity for Alpha 2 Receptors Activity
Nanoparticulate meloxicam formulations
Reduction of Intravenously Administered Nanoparticulate-Formulation-Induced Adverse Physiological Reactions
Patent:
41,884 →
Application:
12/027,100 →
Nanoparticulate Compositions Having Lysozyme as a Surface Stabilizer
Oral Mucosal Dexmedetomidine Compositions and Methods of Use Thereof
Application:
12/781,628 →
Publication:
US 2011/0021588
Treatment or Prevention of Hypotension and Shock
Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Application:
13/520,959 →
Publication:
US 2013/0072532
Method of Treatment Using Nanoparticulate Compositions Having Lysozyme as a Surface Stabilizer
Intranasal Dexmedetomidine Compositions and Methods of Use Thereof
Treatment or Prevention of Hypotension and Shock
Nanoparticulate Meloxicam Formulations
Application:
13/941,076 →
Publication:
US 2014/0141083
Treatment Or Prevention Of Hypotension And Shock
Nanoparticulate Meloxicam Formulations
Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Nanoparticulate Meloxicam Formulations
Nanoparticulate Meloxicam Formulations
Application:
15/950,539 →
Publication:
US 2018/0228810
Method of Treating Pain in Elderly Patients with Mild Renal Impairment
Methods of Administering Intravenous Meloxicam in a Bolus Dose
Nanoparticulate Meloxicam Formulations
Application:
16/507,796 →
Publication:
US 2020/0155564
Nanoparticulate Meloxicam Formulations
Reduction of Intravenously Administered Nanoparticulate-Formulation- Induced Adverse Physiological Reactions
Application:
60/004,488 →
Nanoparticulate compositions having lysozyme as a surface stabilizer
Application:
60/353,230 →
Nanoparticulate meloxicam formulations
Application:
60/450,705 →
Sublingual Dexmedetomidine Spray Compositions and Methods of Use Thereof
Application:
61/178,730 →
Topical Transdermal Dexmedetomidine Compositions and Methods of Use Thereof
Application:
61/293,440 →
Intranasal Dexmedetomidine Compositions And Methods Of Use Thereof
Application:
61/569,255 →
Method of Treating Pain in Elderly Patients with Mild Renal Impairment
Application:
62/640,232 →
Methods of Administering Intravenous Meloxicam in a Bolus Dose
Application:
62/652,656 →
Methods of Administering Intravenous Meloxicam Pre-Operatively and in Combination with Other Drugs
Application:
62/749,407 →
Methods of Treating Patients Having Platelet Dysfunction with Iv Meloxicam
Application:
62/757,003 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Patent Security Agreement (First Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
Patent Security Agreement (Second Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
Asset Transfer Agreement
Oct 2, 2012
From: ELAN PHARMA INTERNATIONAL LIMITED
To: EDT PHARMA HOLDINGS LIMITED
Reel/Frame 029066/0655 →
Change of Name
Oct 2, 2012
From: EDT PHARMA HOLDINGS LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 029064/0645 →
Assignment of Assignor's Interest
Oct 10, 2012
From: ELAN PHARMA INTERNATIONAL LIMITED
To: EDT PHARMA HOLDINGS LIMITED
Reel/Frame 029103/0465 →
Change of Name
Oct 10, 2012
From: EDT PHARMA HOLDINGS LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 029103/0695 →
Asset Transfer Agreement
Oct 10, 2012
From: ELAN PHARMA INTERNATIONAL LIMITED
To: EDT PHARMA HOLDINGS LIMITED
Reel/Frame 029108/0426 →
Change of Name
Oct 10, 2012
From: EDT PHARMA HOLDINGS LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 029104/0071 →
Release by Secured Party (Second Lien)
Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
Assignment of Assignor's Interest
Dec 3, 2012
From: HENWOOD, GERALDINE A.; MACK, RANDALL J.; SHARR, CHRISTOPHER T.; KOLENG, JOHN J., JR.
To: RECRO PHARMA, INC.
Reel/Frame 029392/0378 →
Assignment of Assignor's Interest
Jul 16, 2013
From: HEINO, RIITTA; LEINO, TIINA; LEHTIMAKI, TARJA
To: ORION CORPORATION
Reel/Frame 030801/0871 →
Assignment of Assignor's Interest
Jul 16, 2013
From: ORION CORPORATION
To: RECRO PHARMA, INC.
Reel/Frame 030801/0881 →
Assignment of Assignor's Interest
Sep 27, 2013
From: HEINO, RIITTA; LEINO, TIINA; LEHTIMAKI, TARJA
To: ORION CORPORATION
Reel/Frame 031300/0565 →
Assignment of Assignor's Interest
Oct 16, 2013
From: HENWOOD, GERALDINE A.; MACK, RANDALL J.; KOLENG, JOHN JOSEPH, JR.; SHARR, CHRISTOPHER T.
To: RECRO PHARMA, INC.
Reel/Frame 031415/0268 →
Assignment of Assignor's Interest
Nov 8, 2013
From: RECRO PHARMA, INC.
To: MALVERN CONSULTING GROUP, INC.
Reel/Frame 031571/0794 →
Assignment of Assignor's Interest
Nov 8, 2013
From: RECRO PHARMA, INC.
To: MALVERN CONSULTING GROUP, INC.
Reel/Frame 031571/0676 →
Assignment of Assignor's Interest
Nov 8, 2013
From: RECRO PHARMA, INC.
To: MALVERN CONSULTING GROUP, INC.
Reel/Frame 031571/0731 →
Corrective Assignment to Correct the Assignor and Assignee Information Previously Recorded on Reel 031571 Frame 0731. Assignor(S) Hereby Confirms the Correct Assignor Is Malvern Consulting Group, Inc. and the Correct Assignee Is Recro Pharma, Inc..
Nov 12, 2013
From: MALVERN CONSULTING GROUP, INC.
To: RECRO PHARMA, INC.
Reel/Frame 031626/0586 →
Corrective Assignment to Correct the Assignor and Assignee Information and Remove the Additional Property Previously Recorded on Reel 031571 Frame 0794. Assignor(S) Hereby Confirms the Correct Assignor Is Malvern Consulting Group, Inc. and the Correct Assignee Is Recro Pharma, Inc.
Nov 12, 2013
From: MALVERN CONSULTING GROUP, INC.
To: RECRO PHARMA, INC.
Reel/Frame 031626/0634 →
Corrective Assignment to Correct the Assignor and Assignee Information Previously Recorded on Reel 031571 Frame 0676. Assignor(S) Hereby Confirms the Correct Assignor Is Malvern Consulting Group, Inc. and the Correct Assignee Is Recro Pharma, Inc..
Nov 12, 2013
From: MALVERN CONSULTING GROUP, INC.
To: RECRO PHARMA, INC.
Reel/Frame 031626/0604 →
Change of Name
Apr 12, 2014
From: EDT PHARMA HOLDINGS LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 032661/0663 →
Asset Transfer Agreement
Apr 12, 2014
From: ELAN PHARMA INTERNATIONAL LIMITED
To: EDT PHARMA HOLDINGS LIMITED
Reel/Frame 032672/0001 →
Property Transfer Agreement
Aug 12, 2014
From: ALKERMES PHARMA IRELAND LIMITED
To: ALKERMES SCIENCE ONE LIMITED
Reel/Frame 033522/0048 →
Change of Name
Mar 27, 2015
From: ALKERMES SCIENCE ONE LIMITED
To: DARAVITA LIMITED
Reel/Frame 035279/0701 →
Asset Transfer and License Agreement
Apr 10, 2015
From: ALKERMES PHARMA IRELAND LIMITED
To: DV TECHNOLOGY LLC
Reel/Frame 035410/0001 →